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1. Introduction 
Although radioimmunoassay techniques [l-3] 
have revolutionized both research and clinical meth- 
odology, recognition of problems associated with 
radioactive materials, uch as effective waste disposal, 
potential health hazards, and short half-life of some 
isoptotes, have prompted searches for non-radioactive 
markers in immunological ssays. Because of the sen- 
sitivity, ease of measurement, good stability and 
longer shelf-life, enzymes have proven to be a good 
substitute as markers in non-isotopic immunoassays 
[4-61. 
Enzyme immunoassays are of two types, hetero- 
geneous and homogeneous. The heterogeneous ones 
require a physical separation of the unbound antigen 
from that bound to the antibody, whereas the homo- 
geneous assay does not. Homogeneous enzyme 
immunoassays have been developed along the follow- 
ing approaches: 
(3 An enzyme is covalently labeled with a ligand 
(the analyte), and the antibody to the ligand 
modulates the activity of the enzyme by either 
inhibiting its activity [7] or activating its activity 
PI; 
An enzyme substrate iscovalently labeled with a 
ligand so that the binding of the ligand-substrate 
conjugate by the antibody to the ligand sterically 
prevents the enzyme from acting on the substrate 
[91; 
(iii) A ligand covalently bound to a prosthetic group 
aud an antibody to that ligand prevents the pros- 
thetic group from combining with an appropriate 
apoenzyme. Such prosthetic group modulated 
enzyme immunoassays have been developed for 
measurement of haptens and human immuno- 
globulin G [lo]. 
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Here we describe adifferent approach to homoge- 
neous enzyme immunoassays, one that employs an 
enzyme modulator (Emmia). An enzyme modulator 
may be an antibody, inhibitor or receptor to the 
marker (i.e., indicator) enzyme. The modulator must 
be covalently linked to a ligand that is similar to the 
analyte so that the amount of modulator free to regu- 
late the available indicator enzyme is dependent upon 
the amount of analyte to be determined. 
2. Principles of Emmia 
The principles of Emmia can be illustrated in the 
following reaction sequences. 
(a) Antibody binding of &and-substituted modulator 
Ab, + L-M -Ab, : L-M 
when Ab, is antibody to the ligand, L is the analyte, 
and L-M is the modulator, M, having the ligand, L, 
covalently linked to it. 
(b) Competitive antibody binding of analy te (L) and 
Iigand-substituted modulator (L-M) 
L+L-MtAb L,mAbL : LtAbL : L-M 
(c)Modulation of indicator enzyme 
E+L-M ,-EEL-M 
when E is indicator enzyme and E of EL-M is 
enzymatically inactive. 
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(d) Indicator reaction 
Substrates & Measurable products 
In Emmia the amount of analyte, L, is determined 
by the decrease in indicator enzyme, E, (measured by 
reaction (d)) caused by its being complexed by a fmed 
amount of the ligand-substituted modulator, L-M, 
(reaction (c)). The amount of L-M available to com- 
plex E is dependent upon the amount of analyte, L, 
because both L and L-M compete for a fixed amount 
of the antibody to L, Ab, (reaction (b)). Thus, the 
lower the concentration of L, the more Ab, will be 
available to complex with L-M (reaction (a)) so that 
indicator enzyme E will be less affected as in reaction 
(c) and will be free to act. On the other hand, more 
analyte L will tie up more Ab, (reaction (b)) freeing 
L-M so that it will react with E (reaction (c)) making 
less E available to catalyze indicator (reaction (d)). 
Hence, the enzyme activity measured will be ‘inversely 
proportional to the amount of analyte present and 
binding to Ab,. 
2.1. Emmia reactants of model system 
In the system we have developed to demonstrate 
Emmia, we use the following components: (I) for L, 
dinitrophenyllysine (DNP-1~s); (II) for Ab,, antibody 
to DNP (AbDNP); (III) for E, peroxidase (POD); and 
(IV), for’M, DNP linked to anti-peroxidase (DNP- 
AbPOD). 
3. Materials and methods 
Horseradish peroxidase (type VI), purified anti- 
horseradish peroxidase (produced in rabbits), 2,4- 
dinitrofluorbenzene and N-e-DNP-LLysine . HCl 
were-purchased from Sigma Chem., St Louis, MO. 
Antiserum to 2,4-dinitrophenol was purchased from 
Miles Lab., Elkhart, IN. 3-Methyl-2-benzothiazoline 
hydrazone hydrochloride monohydrate and 3dime- 
thyl-benzoic acid were purchased from Aldrich Chem., 
Milwaukee, Wl. 
The 2,4-dinitrophenylated anti-horseradish per- 
oxidase was prepared as follows: 10 mg antibody to 
horseradish peroxidase were dissolved in 2 ml of 0.1 M 
sodium phosphate (pH 7.0). To this antibody solu- 
tion was added 10 @2,4dinitrofluorbenzene in 
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dioxane (62 mg/ml). The solution was stirred at room 
temperature for 3 h, then dialyzed 3 times against 
2 liters 0.1 M sodium phosphate (pH 7.0) at 4°C for 
8 hr each. Using 2,4_dinitrophenyllysine as standards 
20.2,4-dinitrophenyl groups/antibody molecule 
was determined. 
The peroxidase assay was performed according to 
[ 111. The 1 ml assay solution in 0.1 pmol sodium 
phosphate (pH 7.0) contained 3.5 ~mol3dimethyl- 
aminobenzoic acid and 0.075 pmol3-methyl-2-benzo- 
thiazoline hydrazone. 
4. Results 
4.1. The indicator and modulator reactions 
Antibody to POD labeled with 2,4dinitrophenyl 
groups is able to inhibit the peroxidase reaction up to 
75% of that inhibited by the unlabeled Ab,,. Fig.1 
shows the activity of horseradish peroxidase 
decreased with increasing amounts of DNP-Ab,O,. 
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Fig.1. The inhibition of peroxidase activity by DNA-AbPOD. 
Peroxidase (0.1 c(g) was incubated at 25” in 0.4 ml 0.1 M 
sodium phosphate (pH 7 .O) containing varying concentrations 
of DNP-AbPOD. After 5 min 0.2 ml of this solution was 
added to 1 ml peroxidase assay solution and the initial rate 
was determined. In the absence of the antibody the peroxi- 
dase gave ti = 0,57/min. 
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4.2. The antibody-binding reaction 
The antibody to the 2,4-dinitrophenyl groups 
(AbDNP) was able to diminish the inhibitory proper- 
ties of DNP-Ab,, . Fig.2 shows that when the per- 
oxidase was inhibited by the DNP-Ab,, to 35% of 
its original activity, the addition of increasing amounts 
of Ab,,, to a solution of the inhibited peroxidase 
resulted in proportional increases in peroxidase activ- 
ity to 90% of that originally present. 
4.3. The competitive-binding reaction 
DNP-Ab,, was shown to compete successfully 
with DNP-Lys for Ab,N, thereby releasing DNP- 
AbPO, free to bind with and inhibit the POD. Fig.3 
showed that when the concentrations of peroxidase, 
DNP-AbR,, and Ab,,R were kept constant in buffer 
solutions, the additions of increasing amounts of DNP- 
Lys resulted in decreasing enzyme acitivity. Thus the 
concentration of DNP-Lys in an analyte solution can 
be measured by such a standard curve. 
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Fig.2. Reversal by AbDNR on the inhibition of peroxidase 
caused by DNF’-AbROD. DNP-AbpOD (240 pg), varying 
amounts of AbDNp and POD (0.1 pg) in 0.3 ml 0.1 M sodi- 
um phosphate (pH 7.0) were incubated at 25°C for 5 mm. 
Then 0.2 ml this solution was added to 1 ml peroxidase assay 
solution to determine the initial rate. 
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Fig.3. The standard curve for DNP-lysine by Emmia. Solu- 
tions of 100 ~1 containing various amounts of DNP-Lys were 
added to 300 r.11 solutions containing 240 @g DNO-AbpOD, 
20 f.d AbDNp and 0.1 pg peroxidase. The solutions were 
incubated at 25’C; after 5 mm, 200 ~1 was added to 1 ml per- 
oxidase assay solution to determine the initial rates. 
5. Discussion 
We have described a new approach to homogeneous 
enzyme immunoassays called enzyme modulator 
mediated immunoassay (Emmia) and have presented 
experimental results verifying its feasibility. The over- 
all process of Emmia can be summarized in scheme (1) 
representing our experimental results. Reactions 
(a-d) refer to those described in section 2. 
It is clear from scheme (1) that in the absence of 
analyte, reaction (b) would not occur and that the 
modulator and antibody to the analyte would com- 
bine (reaction (a)) leaving most of the indicator 
enzyme free to act. As the concentration of analyte 
increases, however, it would compete successfully for 
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Scheme 1 
DNP-lys (analyte) 
(b) 
DNP-lys:AbDNp 
AbDNP (antibody to analyte) 
/,---------b 
DNP-AbpOD (modulator) 
FL 
DNP-AbpOD:AbDNp 
POD 
(Indicator enzyme) 
DNP-AbpOD: POD 
(Enzymatically inactive) 
chromogen colored product 
binding sites on Ab,, (reaction (b)) leaving more 
modulator (DNP-Ab,& free to complex with indi- 
cator enzyme (reaction (c)) thereby inactivating it. 
The overall result is, therefore, as the amount of 
analyte increases, the amount of chromogen converted 
by the remaining indicator enzyme (reaction(d)) will 
decrease. The results presented in fig.l-3 bear out 
the validity of this approach to homogeneous enzyme 
immunoassay. 
Unlike the substrate-labeled enzyme immunoassay 
that uses ligand substituted substrate [9], this 
approach provides an intrinsic amplifying power 
because any uninhibited enzyme can continuously 
generate products. 
An advantage of Emmia over heterogeneous a says 
is that it eliminates the cumbersome step of physically 
separating the unbound and the antibody bound anti- 
gens. 
The successful development of Emmia requires the 
availability of an enzyme modulator having a high 
affinity for the enzyme. There are numerous com- 
pounds which qualify. For example, the modulator 
can be: 
(i) An enzyme inhibitor, such as avidin which can 
inhibit biotin dependent enzymes by high affinity 
binding [12]; 
(ii) A transition-state analog, such as coformycin, 
which inhibits adenosine deaminase with an inhi- 
bition constant of 10-‘“-lO-” M [13]; 
(iii) An activator, such as an antibody to the wild- 
type Escherichia coli /3-galactosidase, which can 
activate SSO-fold the activity of a mutant enzyme 
known to be inactive by itself [ 141. 
We believe that the concept of Emmia is sufficiently 
versatile and specific to be a useful addition to the 
field of homogeneous enzyme immunoassays. 
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